Increased Serum Level of CCL5 in Children with Attention‑Deficit/Hyperactivity Disorder: First Results about Serum Chemokines

키워드

참고문헌 (49)

1. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Pub
2. Willcutt EG, "The prevalence of DSM-IV attention-deficit", hyperactivity disorder : a meta-analytic review, 2012, pp.9, 490~499
3. Ercan ES, "Is the prevalence of ADHD in Turkish elementary school children really high?", Soc Psychiatry Psychiatr Epidemiol, 50, pp.1145~1152 (2015)
4. Faraone SV, "Genetics of attention deficit hyperactivity disorder", Mol Psychiatry, 24, pp.562~575 (2019)
5. Thapar A, "What have we learnt about the causes of ADHD?", J Child Psychol Psychiatry, 54, pp.3~16 (2013)
6. Ceylan MF, "Increased levels of serum neopterin in attention deficit", hyperactivity disorder(ADHD), 2014, pp.273, 111~114
7. Darwish AH, "Serum interleukin-6level in children with attention-deficit hyperactivity disorder(ADHD)", J Child Neurol, 34, pp.61~67 (2019)
8. Mitchell RH, "Inflammation in children and adolescents with neuropsychiatric disorders : a systematic review", J Am Acad Child Adolesc Psychiatry, 53, pp.274~296 (2014)
9. Dunn GA, "Neuroinflammation as a risk factor for attention deficit hyperactivity disorder", Pharmacol Biochem Behav, 182, pp.22~34 (2019)
10. Teixeira AL, "Increased serum levels of CCL11", eotaxin in schizophrenia, 2008, pp.32, 710~714
11. Rostène W, "Neurochemokines : a menage a trois providing new insights on the functions of chemokines in the central nervous system", J Neurochem, 118, pp.680~694 (2011)
12. Le Thuc O, "The complex contribution of chemokines to neuroinflammation : switching from beneficial to detrimental effects", Ann N Y Acad Sci, 1351, pp.127~140 (2015)
13. Bajetto A, "Chemokines and their receptors in the central nervous system", Front Neuroendocrinol, 22, pp.147~184 (2001)
14. Stuart MJ, "Systematic review of the neurobiological relevance of chemokines to psychiatric disorders", Front Cell Neurosci, 9, pp.357~ (2015)
15. Teixeira AL, "Revisiting the role of eotaxin-1", CCL11 in psychiatric disorders, 2018, pp.9, 241~
16. Di Prisco S, "RANTES-mediated control of excitatory amino acid release in mouse spinal cord", J Neurochem, 121, pp.428~437 (2012)
17. Simon NM, "A detailed examination of cytokine abnormalities in Major Depressive Disorder", Eur Neuropsychopharmacol, 18, pp.230~233 (2008)
18. Han YM, "Distinct cytokine and chemokine profiles in autism spectrum disorders", Front Immunol, 8, pp.11~ (2017)
19. Sayana P, "A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients", J Psychiatr Res, 92, pp.160~182 (2017)
20. Vargas DL, "Neuroglial activation and neuroinflammation in the brain of patients with autism", Ann Neurol, 57, pp.67~81 (2005)
21. Ashwood P, "Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome", Brain Behav Immun, 25, pp.40~45 (2011)
22. Ogłodek EA, "Comparison of chemokines(CCL-5 and SDF-1), chemokine receptors(CCR-5 and CXCR-4)and IL-6 levels in patients with different severities of depression", Pharmacol Rep, 66, pp.920~926 (2014)
23. Barbosa IG, "Chemokines in bipolar disorder : trait or state?", Eur Arch Psychiatry Clin Neurosci, 263, pp.159~165 (2013)
24. Dereboy C, "Validation of the Turkish versions of the short-form Conners’ teacher and parent rating scales", Turk Psikiyatri Derg, 18, pp.48~58 (2007)
25. Allred EN, "Systemic inflammation during the first postnatal month and the risk of attention deficit hyperactivity disorder characteristics among 10 year-old children born extremely preterm", J Neuroimmune Pharmacol, 12, pp.531~543 (2017)
26. Kozłowska A, "ADHD pathogenesis in the immune, endocrine and nervous systems of juvenile and maturating SHR and WKY rats", Psychopharmacology(Berl), 236, pp.2937~2958 (2019)
27. Donfrancesco R, "Serum cytokines in paediatric neuropsychiatric syndromes : focus on Attention Deficit Hyperactivity Disorder", Minerva Pediatr (2016)
28. Oades RD, "Attention-deficit hyperactivity disorder(ADHD)and glial integrity : S100B, cytokines and kynurenine metabolism--effects of medication", Behav Brain Funct, 6, pp.29~ (2010)
29. Skuljec J, "CCL5 induces a pro-inflammatory profile in microglia in vitro", Cell Immunol, 270, pp.164~171 (2011)
30. Anand D, "Attentiondeficit", hyperactivity disorder and inflammation: what does current knowledge tell us? A systematic review, 2017, pp.8, 228~
31. Alvarez-Arellano L, "Antioxidants as a potential target against inflammation and oxidative stress in attention-deficit", hyperactivity disorder, 2020, pp.9, 176~
32. Chandra G, "Neutralization of RANTES and eotaxin prevents the loss of dopaminergic neurons in a mouse model of Parkinson disease", J Biol Chem, 291, pp.15267~15281 (2016)
33. Dutta D, "RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson’s disease", Neurobiol Dis, 132, pp.104575~ (2019)
34. Roy A, "Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8＋ T cells in the nigra of hemiparkinsonian monkey", Neuroscience, 302, pp.36~46 (2015)
35. Mehler-Wex C, "Dopaminergic dysbalance in distinct basal ganglia neurocircuits : implications for the pathophysiology of Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder", Neurotox Res, 10, pp.167~179 (2006)
36. Kehagia AA, "Targeting impulsivity in Parkinson’s disease using atomoxetine", Brain, 137(Pt 7), pp.1986~1997 (2014)
37. Hirsch EC, "Neuroinflammation in Parkinson’s disease : a target for neuroprotection?", Lancet Neurol, 8, pp.382~397 (2009)
38. Romanos M, "Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder", J Psychiatry Neurosci, 35, pp.55~58 (2010)
39. Warton FL, "Increased glutamatestimulated release of dopamine in substantia nigra of a rat model for attention-deficit", hyperactivity disorder--lack of effect of methylphenidate, 2009, pp.24, 599~613
40. Volkow ND, "Brain dopamine transporter levels in treatment and drug naïve adults with ADHD", Neuroimage, 34, pp.1182~1190 (2007)
41. MacMaster FP, "Proton spectroscopy in medication-free pediatric attention-deficit", hyperactivity disorder, 2003, pp.53, 184~187
42. Bollmann S, "Developmental changes in gamma-aminobutyric acid levels in attention-deficit", hyperactivity disorder, 2015, pp.5, e589~
43. Lasky-Su J, "Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations", Am J Med Genet B Neuropsychiatr Genet, 147B, pp.1345~1354 (2008)
44. Huang X, "The role of glutamate receptors in attention-deficit", hyperactivity disorder : from physiology to disease, 2019, pp.180, 272~286
45. Miller EM, "Aberrant glutamate signaling in the prefrontal cortex and striatum of the spontaneously hypertensive rat model of attention-deficit", hyperactivity disorder, 2014, pp.231, 3019~3029
46. Banisadr G, "Distribution, cellular localization and functional role of CCR2 chemokine receptors in adult rat brain", J Neurochem, 81, pp.257~269 (2002)
47. van der Meer P, "Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain : potential mechanisms for HIV dementia", Exp Mol Pathol, 69, pp.192~201 (2000)
48. Masi A, "Cytokine aberrations in autism spectrum disorder : a systematic review and meta-analysis", Mol Psychiatry, 20, pp.440~446 (2015)
49. Medin T, "Low dopamine D5 receptor density in hippocampus in an animal model of attention-deficit", hyperactivity disorder(ADHD), 2013, pp.242, 11~20

관련 논문AI추천